Elevation Oncology Investor Relations Material
Latest events
Study Update
Elevation Oncology
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Elevation Oncology Inc
Access all reports
Elevation Oncology, Inc. is a biotechnology company focused on the discovery and development of targeted cancer therapies. The company specializes in creating antibody-drug conjugates (ADCs) to treat patients with solid tumors that have significant unmet medical needs. Their lead candidate, EO-3021, targets the Claudin 18.2 protein, which is expressed in various cancers, including gastric and pancreatic cancers. Elevation Oncology aims to selectively deliver cytotoxic agents directly to cancer cells, thereby improving treatment efficacy while minimizing damage to healthy tissues. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Key slides for Elevation Oncology Inc
Study Update
Elevation Oncology Inc
Study Update
Elevation Oncology Inc
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
ELEV
Country
🇺🇸 United States